Want to see AU:CUV full AI Analyst Report?

Clinuvel Pharmaceuticals (CUV) Price & Analysis

112 Followers

CUV Stock Chart & Stats

AU$11.08

-AU$0.31(-2.63%)

At close: Jan 09 4:00 PM EST

AU$11.08

-AU$0.31(-2.63%)

Day’s Range― - ―

52-Week RangeAU$8.35 - AU$14.00

Previous CloseN/A

Volume193.84K

Average Volume (3M)97.23K

Market Cap

AU$506.80M

Enterprise ValueAU$398.04

Total Cash (Recent Filing)AU$233.00M

Total Debt (Recent Filing)AU$341.09K

Price to Earnings (P/E)15.2

Beta0.74

Next Earnings

Sep 01, 2026

EPS Estimate

0.45

Next Dividend Ex-DateN/A

Dividend Yield0.51%

Share Statistics

EPS (TTM)0.65

Shares Outstanding50,427,900

10 Day Avg. Volume118,433

30 Day Avg. Volume97,231

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.16

Price to Sales (P/S)5.47

P/FCF Ratio12.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$28.10

Price Target Upside153.61% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.74

Revenue Forecast (FY)AU$106.08M

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet & Cash ReservesClinuvel's large cash balance (A$233m) and two decades of zero debt provide a durable funding base to support clinical programs, commercial scale-up and ADR/NASDAQ work without near-term financing. Term deposits yielding ~4.5% also generate recurring interest, extending runway for 2–6+ months of strategic activity.

Sustained Profitability And Cash GenerationTwenty consecutive profitable periods and healthy operating cash flow reflect durable underlying economics and efficient cost control in a biotech. Consistent profitability reduces dilution risk, funds organic R&D/commercial investment, and gives management flexibility to pursue strategic milestones over the medium term.

Commercial Execution & Market Access ExpansionRegulatory label expansion in Europe and established US site coverage materially raise addressable implant volume and recurring dosing opportunity. Broader market access and geographical diversification underpin steadier revenue streams and reduce single-market dependency, supporting sustained sales over the coming months.

Bears Say

Slowing Revenue GrowthRevenue growth is modest (H1 +4%, revenue growth ~5.2%), reflecting the limited expansion pace typical in rare-disease markets. Slow top-line momentum may constrain the return on increased R&D and commercial spend and lengthen the time to scale new indications or offsets from higher operating costs.

Material Expense Growth And FCF VariabilityManagement has materially increased spending (personnel +16%, R&D +191%, distribution +42%), which compresses near-term net income despite cash reserves. Fluctuations in free cash flow to net income create planning uncertainty and raise execution risk if higher burn precedes revenue gains from new indications or commercialization efforts.

Regulatory & Program Timing RiskThe requirement to finish CUV107 before filing and outstanding SEC feedback on ADR/NASDAQ creates real timing risk for vitiligo approvals and for perceived U.S. listing benefits. Delays can defer revenue diversification, extend reliance on SCENESSE and increase the duration of elevated operating costs.

Clinuvel Pharmaceuticals News

Clinuvel shifts headquarters to U.S. in strategic overhaul

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals will relocate its corporate headquarters...

1d ago

Clinuvel Starts Trading Level II ADS on Nasdaq Under CUVL

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. Clinuvel Pharmaceuticals has expanded its U.S. market presence by...

2d ago

Clinuvel wins Health Canada approval for rare‑disease drug SCENESSE

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an announcement. Clinuvel Pharmaceuticals has secured Health Canada’s Notice of Compliance...

11d ago

Clinuvel Extends CEO’s Term to 2029 as Board Backs Ambitious Expansion Plan

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an update. Clinuvel Pharmaceuticals has extended the employment agreement of CEO...

22d ago

Clinuvel Files 20-F as It Pursues Nasdaq ADS Uplisting

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals has publicly filed a Form 20-F registration...

1M ago

Clinuvel Issues 887,956 Unquoted Performance Rights Under Incentive Scheme

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals has notified the market of the issue...

3M ago

Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals is a Melbourne‑based specialty drug developer focused...

3M ago

FDA Drops QT Study Requirement for Clinuvel’s SCENESSE

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals said the U.S. Food and...

3M ago

Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals has received final scientific advice from the...

3M ago

Clinuvel Performance Rights Lapse After Conditions Not Met

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an announcement. Clinuvel Pharmaceuticals has announced the cessation of 46,067 performance...

3M ago

CUV FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest share price was AU$8.35 and its highest was AU$14.00 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is AU$506.80M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 40 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported AU$0.206 earnings per share for the quarter, missing the consensus estimate of AU$0.293 by -AU$0.087.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.51%. See more information on Clinuvel Pharmaceuticals Limited dividends here

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.45.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,427,900 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.206 in its last earnings report, missing expectations of AU$0.293. Following the earnings report the stock price went down -3.243%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:CUV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

0.51%

Trailing 12-Months

Asset Growth

22.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Clinuvel Pharmaceuticals (CUV) Earnings & Revenues

Historic Earnings Reports

CUV Stock 12 Month Forecast

Average Price Target

AU$28.10

▲(153.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"AU$8","16":"AU$16","24":"AU$24","32":"AU$32","40":"AU$40"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$39.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$28.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16,24,32,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,12.633846153846154,14.847692307692308,17.06153846153846,19.275384615384617,21.48923076923077,23.70307692307692,25.916923076923077,28.130769230769232,30.344615384615388,32.558461538461536,34.77230769230769,36.98615384615385,{"y":39.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,11.78,13.14,14.5,15.86,17.22,18.58,19.939999999999998,21.299999999999997,22.659999999999997,24.019999999999996,25.38,26.740000000000002,{"y":28.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,10.926153846153847,11.432307692307692,11.938461538461539,12.444615384615386,12.95076923076923,13.456923076923077,13.963076923076922,14.46923076923077,14.975384615384616,15.481538461538461,15.987692307692308,16.493846153846153,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.071,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.668,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.17,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >